Literature DB >> 7923194

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.

A Rahman1, K R Korzekwa, J Grogan, F J Gonzalez, J W Harris.   

Abstract

The principal taxol biotransformation reaction of humans and of human hepatic in vitro preparations is 6 alpha-hydroxylation of the taxane ring, but a separate, minor hydroxylation pathway (metabolite B formation) also exists. Taxol metabolism was studied using membrane fractions from Hep G2 cells infected with recombinant vaccinia viruses that contain complementary DNAs encoding several human cytochrome P450 enzymes. Only P450 2C8 formed detectable 6 alpha-hydroxytaxol. Metabolite B formation was catalyzed by complementary DNA-expressed 3A3 and 3A4, but not by 3A5. Each P450 3A preparation catalyzed felodipine oxidation. The apparent Km and Vmax values for taxol 6 alpha-hydroxylation were 5.4 +/- 1.0 microM and 30 +/- 1.5 nmol/min/nmol P450, respectively, for complementary DNA-expressed P450 2C8; the values were 4.0 +/- 1.0 microM and 0.87 +/- 0.06 nmol/min/mg protein, respectively, for human hepatic microsomes. The inhibition of 6 alpha-hydroxytaxol formation by quercetin was competitive with an apparent Ki of 1.3 or 1.1 microM with 2C8 or hepatic microsomes, respectively; retinoic acid was inhibitory, showing an apparent Ki of 27 microM with hepatic microsomes; inhibition by tolbutamide was complex, weak, and unlikely to be clinically relevant. The correlation between hepatic 2C8 protein content and 6 alpha-hydroxytaxol formation was high (r2 = 0.82), while the correlation with 2C9 content was low (r2 = 0.38). These data show that human biotransformation routes of taxol result from catalysis by specific enzymes of two P450 families and that taxol 6 alpha-hydroxylation is a useful indicator of P450 2C8 activity in human hepatic microsomes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923194

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  81 in total

1.  Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes.

Authors:  Kyoung-Ah Kim; Jaegul Chung; Dong-Hae Jung; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2004-09-08       Impact factor: 2.953

2.  The design of in vitro liver sinusoid mimics using chitosan-hyaluronic acid polyelectrolyte multilayers.

Authors:  Yeonhee Kim; Adam L Larkin; Richey M Davis; Padmavathy Rajagopalan
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

3.  Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver.

Authors:  Shu-Yun Zhang; Sailesh Surapureddi; Sherry Coulter; Stephen S Ferguson; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2012-06-20       Impact factor: 4.436

4.  In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8).

Authors:  Chia Yong Pang; Joon Wah Mak; Rusli Ismail; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-04       Impact factor: 3.000

Review 5.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 6.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 7.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

9.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Arch Biochem Biophys       Date:  2007-04-10       Impact factor: 4.013

Review 10.  A preliminary risk-benefit assessment of paclitaxel.

Authors:  R J Bitton; W D Figg; E Reed
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.